Anti-CGRPs in migraine webinar
Anti-CGRPs in patient-centred migraine management
Learn the aims of this webinar from chair Professor Peter Goadsby (King's College London, UK).
Presentation 1: Mechanism of action of anti-CGRPs in migraine
Professor Antoinette Maassen van den Brink (Erasmus MC, Rotterdam, the Netherlands) explains the rationale for anti-calcitonin gene-related peptides (CGRPs) in people with migraine and highlights the "novel concept" that the different pharmacokinetics of gepants offer a continuum between acute and prophylactic treatments.
Professor Maassen van den Brink responds to questions from Professor Goadsby about her presentation.
Presentation 2: The role of anti-CGRPs in long-term migraine management
According to Professor Goadsby, accumulating long-term anti-CGRP efficacy and safety data “complements our understanding of the disorder and of anti-CGRP medicines”. He reviews long-term outcomes following cessation and resumption of anti-CGRP treatment for migraine and medication overuse.
Presentation 3: Selecting patients for anti-CGRP treatment for acute and preventative migraine
Professor Goadsby and Professor Maassen van den Brink discuss patient selection for anti-CGRP treatment.
Q&A session
In this Q&A session, Professor Goadsby and Professor Maassen van den Brink address audience questions on anti-CGRPs.
You can navigate the audience questions using the following chapters:
Question 1: Would you recommend these therapies in developing countries?
Question 2: Is it possible for the practitioner and the patient to predict benefit from the anti-CGRPs for migraine?
Question 3: Is switching between the anti-CGRPs or the anti-CGRP receptor blocker erenumab useful?
Question 4: Is the efficacy of the anti-CGRPs for migraine the same in all migraine subtypes?
Question 5: Is gene mutation testing needed before suggesting anti-CGRP therapies to patients?
Question 6: Is treatment persistence and adherence better with the anti-CGRPs than with previous migraine preventatives?
Question 7: What is the expected length of benefit of each anti-CGRP drug, that is, do anti-drug antibodies form to these antibodies? Can these be measured?
Question 8: Are any of the anti-CGRPs superior to the others?
Thank you for watching. Please help us improve Medthority by answering the following questions.
Webinar Faculty
Professor Peter Goadsby
Professor Peter Goadsby is Director, NIHR King's Clinical Research Facility, Professor of Neurology, King's College London, an honorary consultant neurologist at King's College Hospital and the Hospital for Sick Children, Great Ormond St, London, UK; and a National Institute for Health and Social Care Research senior investigator.
Professor Goadsby’s major research interests are in the basic mechanisms of primary headache disorders, such as migraine and cluster headache, in both experimental and clinical settings, and translating these insights into better management.
Disclosures
Research grants: Celgene.
Personal fees: Aeon Biopharma, AbbVie, Amgen, CoolTech LLC, Dr Reddy’s Laboratories, Eli Lilly, Epalex, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, ShiraTronics, Teva Pharmaceuticals, Tremeau.
Fees for advice: Gerson Lehrman Group, Guidepoint, SAI MedPartners, Vector Metric.
Fees from educational materials: CME Outfitters
Publishing royalties or fees: Massachusetts Medical Society, Oxford University Press, UptoDate, Wolters Kluwer.
Patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.
Professor Antoinette Maassen van den Brink
Antoinette Maassen van den Brink is Professor of Neurovascular Pharmacology at the Erasmus MC, Rotterdam, the Netherlands. She studies the neurovascular aspects of migraine, with a special interest in the role of female sex hormones in its pathophysiology. Her research is translational in origin, including animal in vivo experimental models, human isolated tissue models, human stem cell-derived models, as well as human in vivo clinical models.
Professor Maassen van den Brink is a board member of the Dutch Headache Society and founding board member of the Dutch Society for Gender and Health. She is President-elect of the European Headache Federation. She has received many prestigious research grants, including the VENI, VIDI and VICI grants from the Dutch Research Council.
Disclosures
Research grants, consulting, speaker fees: Allergan/AbbVie, Amgen/Novartis, Eli Lilly, Pfizer, Satsuma, Teva Pharmaceuticals, Tonix Pharmaceuticals.
of interest
are looking at
saved
next event
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.